Cold Plasma-Treated Ringer's Saline: A Weapon to Target Osteosarcoma.
Miguel Mateu-SanzJuan TornínBénédicte BrulinAnna KhlyustovaMaria-Pau GinebraPierre LayrolleCristina CanalPublished in: Cancers (2020)
Osteosarcoma (OS) is the main primary bone cancer, presenting poor prognosis and difficult treatment. An innovative therapy may be found in cold plasmas, which show anti-cancer effects related to the generation of reactive oxygen and nitrogen species in liquids. In vitro models are based on the effects of plasma-treated culture media on cell cultures. However, effects of plasma-activated saline solutions with clinical application have not yet been explored in OS. The aim of this study is to obtain mechanistic insights on the action of plasma-activated Ringer's saline (PAR) for OS therapy in cell and organotypic cultures. To that aim, cold atmospheric plasma jets were used to obtain PAR, which produced cytotoxic effects in human OS cells (SaOS-2, MG-63, and U2-OS), related to the increasing concentration of reactive oxygen and nitrogen species generated. Proof of selectivity was found in the sustained viability of hBM-MSCs with the same treatments. Organotypic cultures of murine OS confirmed the time-dependent cytotoxicity observed in 2D. Histological analysis showed a decrease in proliferating cells (lower Ki-67 expression). It is shown that the selectivity of PAR is highly dependent on the concentrations of reactive species, being the differential intracellular reactive oxygen species increase and DNA damage between OS cells and hBM-MSCs key mediators for cell apoptosis.
Keyphrases
- poor prognosis
- induced apoptosis
- cell cycle arrest
- dna damage
- reactive oxygen species
- long non coding rna
- cell therapy
- oxidative stress
- endothelial cells
- endoplasmic reticulum stress
- signaling pathway
- cell proliferation
- neoadjuvant chemotherapy
- dna repair
- bone marrow
- bone mineral density
- postmenopausal women
- squamous cell
- newly diagnosed
- drug induced
- anti inflammatory
- umbilical cord
- pluripotent stem cells
- childhood cancer